SPECTRA Speeds Autism Diagnosis While Therapy Coverage Tightens

Health secretary Robert F. Kennedy Jr. launched SPECTRA on September 17, 2026, asking ARPA-H to fund tools that speed autism diagnosis and tailor care. The announcement names no dollar figure for the grants.

Families already wait months for those labels. Those labels now feed a therapy market that Medicaid is rewriting after years of fast spending growth and fraud cases.

Four Technical Areas and a Staggered Bid Calendar

SPECTRA stands for Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency. It sits inside the Advanced Research Projects Agency for Health, the HHS unit built to fund high-risk medical bets the way DARPA funds defense tech.

Kennedy said autism is not one-size-fits-all, and that science and care cannot be either. Program manager Russell Shilling said assessment still leans on long behavioral exams by specialists who are scarce in much of the country. ARPA-H wants objective measures, including genetic, exposome, epigenetic, and microbiome data, then computational models of subtypes that can match a person to an intervention.

The solicitation is ARPA-H-SOL-26-163. Teams must file a solution summary before a full proposal, and full proposal dates are still to be announced. There is still no public budget line.

SPECTRA TECHNICAL AREAS AND FIRST DEADLINES

TA 4 opens for summaries on October 4, 2026. TA 1 and TA 2 open on November 18, 2026. TA 3 opens on January 4, 2027. The calendar is on ARPA-H’s page for the four technical areas with staggered due dates.

The hypothesis underneath the paperwork is that nonlinear interactions among genes, environment, family, metabolism, immune function, the microbiome, and development shape different paths. That is also the opening Kennedy’s allies have wanted: a federal program that treats environment as a first-class variable, not a footnote to genetics and better screening.

Most Children Still Wait Months for an Evaluation

The bottleneck SPECTRA cites is real. Reliable diagnosis can be made in toddler years, but most families still reach a specialist only after delays stack up, and many children are identified well after the window when early intervention is easiest to start.

CDC’s Autism and Developmental Disabilities Monitoring Network, reading 2022 records in 16 communities, found about 1 in 31 8-year-olds identified with autism. That is 3.2 percent in those sites, and CDC says it does not necessarily stand for every U.S. child. Identification ranged from 1 in 103 in Laredo, Texas, to 1 in 19 in California.

CDC ADDM SNAPSHOT, 2022 SURVEILLANCE

• Prevalence: About 1 in 31 (3.2%) 8-year-olds in 16 ADDM communities were identified with autism.
• Sex gap: Boys were more than 3 times as likely as girls to be identified.
• Intellectual disability: Among 8-year-olds with a documented IQ score, nearly 40% also had IQ scores of 70 or below.
• Earlier flags: Children born in 2018 were nearly 2 times as likely as children born in 2014 to be identified by age 4.

The same CDC system puts the median age of earliest documented diagnosis at 47 months. An Interagency Autism Coordinating Committee draft plan notes the older marker of about 1 in 150 in surveillance year 2000, which is the climb Kennedy often treats as proof of an environmental driver. Most epidemiologists still put a large share of that climb on broader criteria, more screening, and school identification.

A CMS survey of 111 autism centers in 38 states found nearly two-thirds had wait times longer than 4 months, and 15% reported waits over a year or had closed their lists. No center finished an evaluation in under an hour. A quarter said each evaluation took more than 8 hours. Nearly half, 44%, said they did not take Medicaid.

That is the machine SPECTRA wants to shrink with sensors, home measures, and models. A shorter queue is a genuine gain for parents who now lose a year on a waitlist. It does not, by itself, hire therapists or reopen a denied claim.

Faster Diagnoses Hit a Therapy Squeeze

The main therapy those new labels still point toward is Applied Behavior Analysis. CMS said ABA spending in Medicaid and CHIP increased 421% between 2021 and 2025, far outpacing a 67% rise in the number of children with an autism diagnosis who received services.

On August 4, 2026, CMS published a state toolkit to police that growth. Kennedy said the package helps states shut down fraud schemes that exploit children and waste taxpayer money. Administrator Mehmet Oz said every dollar lost to fraud or waste is a dollar that cannot reach a child who needs it. Federal auditors have already flagged large improper ABA billings, including $77.8 million in Colorado. CMS also pointed to kickback cases and prosecutions.

The toolkit is not a new federal mandate. It does not cut the Early and Periodic Screening, Diagnostic, and Treatment benefit that still requires medically necessary care for Medicaid children under 21. It does tell states to treat ABA like a high-risk benefit.

WHAT THE CMS TOOLKIT TELLS STATES TO TIGHTEN

• Medical necessity: Tie hours to a child’s clinical need, not a standard package sold to every family.
• Diagnosis integrity: Confirm autism through a qualified clinician before paying for comprehensive ABA, with limits on thin telehealth-only exams.
• Who bills: Raise enrollment, credentialing, and supervision rules so untrained staff cannot bill as if they were certified.
• Coding: Pay against ABA-specific codes and separate real clinical supervision from desk work billed as therapy.
• Utilization: Use prior authorization and concurrent review to catch overlapping hours and claims that show no progress.
• Fraud flags: Watch kickbacks, ghost networks, and bills that outrun any plausible day of care.

CMS says the document draws on more than 40 research sources and more than 240 state Medicaid policy texts. Several states have already cut reimbursement or capped weekly hours on their own. Private plans have been in court with large ABA chains over out-of-network billing. A faster SPECTRA label still has to clear that gate before a therapist is paid to show up.

TA 3 and TA 4 do ask for new interventions and for tools that make daily life easier, so the program is not only a diagnostic factory. Those awards, if they come, will be research prototypes. They will not automatically become a Medicaid benefit, and they will not reverse a rate cut.

Kennedy Made the Pitch at Children’s Health Defense

Kennedy announced the research push during a keynote at Children’s Health Defense, the group he used to lead, at the Grand Hyatt in Washington. Andrew Wakefield, whose retracted paper falsely tied the MMR vaccine to autism, was on the same day’s program. Kennedy told the room it had a strong and steadfast friend at the White House, and he used the word “damaged” for children he described as vaccine-injured, including those with autism.

In the HHS release he struck a different register, talking about better answers and better outcomes. At the conference he asked what drives different forms of autism, why some children regress, and which interventions work, and he kept vaccines inside the story of chronic disease. He and President Trump have also tied autism to Tylenol use in pregnancy, a claim that still lacks good evidence. Large studies have not shown that childhood vaccines cause autism.

Autism is not one-size-fits-all, and our science and care cannot be either. Millions of American families are impacted by autism, and they need better answers about why it presents so differently from one person to another and which approaches can best meet each person’s needs.

Robert F. Kennedy Jr., HHS secretary, SPECTRA launch statement, September 17, 2026

That night he posted a launch video in his own name.

We are bringing the full power of American science and innovation to autism.

Today, HHS is launching SPECTRA to pursue better answers, more precise care, and better outcomes for people with autism and their families. pic.twitter.com/DBfnUkzZD0

— Secretary Kennedy (@SecKennedy) September 17, 2026

The first questions around that post were not about wait lists or ABA hour caps. They were about whether the new models will treat vaccines as a cause, and whether the point is a cure. SPECTRA’s written brief does not name vaccines. It does invite environmental, immune, metabolic, and microbiome factors into the same stack as genes, which is enough of an opening for that audience to hear a mandate.

A Former DARPA Officer Will Pick the Winners

Russell Shilling holds the pen on what counts as a bold solution. He is a retired Navy captain and a former DARPA program officer, later chief science officer at the American Psychological Association and head of STEM work at the Education Department. He has two autistic adult sons. He sat on the Medical and Science Advisory Committee at Autism Speaks, and he has spent years pushing accessibility tech rather than a single-cause theory.

Shilling said the field got better at recognizing how much people on the spectrum differ, while assessment and care lagged. He wants devices and models built with autistic people, not only about them, and usable in clinics, schools, and homes. That is a different project from a conference hall that still talks as if autism were an injury to be reversed.

Helen Tager-Flusberg, who directs the Center for Autism Research Excellence at Boston University, called ARPA-H’s turn toward autism timely and said technology could change diagnosis, intervention, and support. She also said she hoped the review would pick projects without bias. The hope is the tell. SPECTRA’s scientific case is strongest if summaries are scored on measurement and outcomes. It weakens if the political brief, find the environmental culprit, starts steering who gets through the door.

NIH Already Funded 13 Projects at $50 Million

SPECTRA is not the administration’s first autism data bet. NIH launched the Autism Data Science Initiative in September 2025 with more than $50 million for 13 projects over 24- to 36-month other-transaction awards. NIH said it reviewed 248 applications. Director Jay Bhattacharya said the work would bring genetics, biology, and environmental exposures together. Alison Singer, president of the Autism Science Foundation, said researchers first feared the money would go to vaccine-injury studies; the funded slate instead spans contaminants, nutrition, services, and a replication hub.

An HHS inspector general review later found NIH followed federal rules when it made those awards. HHS Rapid Response, posting during the September 17, 2026 keynote, also said the Interagency Autism Coordinating Committee is calling to nearly double federal autism research funding. SPECTRA is the DARPA-style sequel: faster, more commercial, less bound to classic peer review, and still silent on cost.

THE FEDERAL AUTISM SEQUENCE UNDER THIS HHS

1. September 2025: NIH opens the Autism Data Science Initiative, more than $50 million across 13 projects.
2. August 4, 2026: CMS releases the state ABA toolkit after a 421% rise in Medicaid and CHIP ABA spending.
3. September 17, 2026: ARPA-H launches SPECTRA and Kennedy keynotes Children’s Health Defense.
4. October 18, 2026: First SPECTRA solution summaries, for enabling technologies, are due at 5:00 p.m. ET.

A widely cited analysis HHS still quotes put annual U.S. autism-related costs at about $461 billion by 2025, counting medical care, support, and lost work. That figure is a cost-of-illness estimate, not a SPECTRA budget. The new program can pay teams to build faster exams and smarter matching tools. It cannot, on this record, staff the clinics or restore the hours insurers are taking back.

The first SPECTRA summaries are due October 18, 2026. A shorter path to a label will still meet the same billing rules, the same hour caps, and the same short bench of therapists unless those move too. ARPA-H has not said how much it will spend to find out.

Disclaimer: This article is news reporting and analysis of a federal research announcement and related Medicaid policy, and it is for information only. It is not medical advice, a diagnosis, or guidance on insurance coverage, and it does not recommend that any family seek, delay, start, or stop an evaluation or therapy. Readers should talk with a qualified physician, psychologist, or other licensed clinician, and with their health plan, before making care or coverage decisions. Program dates, eligibility rules, and spending figures reflect the agency notices cited here and can change as ARPA-H, CMS, and NIH update their materials.